We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 14, 2021

Palbociclib in Combination With Endocrine Therapy vs Capecitabine in HR-Positive, HER2-Negative, Aromatase Inhibitor–Resistant Metastatic Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Palbociclib in Combination With Endocrine Therapy Versus Capecitabine in Hormonal Receptor-Positive, Human Epidermal Growth Factor 2-Negative, Aromatase Inhibitor-Resistant Metastatic Breast Cancer: A Phase III Randomised Controlled Trial – PEARL
Ann. Oncol 2020 Dec 29;[EPub Ahead of Print], M Martin, C Zielinski, M Ruiz-Borrego, E Carrasco, N Turner, EM Ciruelos, M Muñoz, B Bermejo, M Margeli, A Anton, Z Kahan, T Csöszi, MI Casas, L Murillo, S Morales, E Alba, E Gal-Yam, A Guerrero-Zotano, L Calvo, J Haba-Rodriguez, M Ramos, I Alvarez, A Garcia-Palomo, CH Bartlett, M Koehler, R Caballero, M Corsaro, X Huang, JA Garcia-Sáenz, JI Chacón, C Swift, C Thallinger, M Gil-Gil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading